US FTC scrutiny reduced Orange Book protections for 19 drugs, study finds
Requests by the Federal Trade Commission to delist over 400 medical device patents from the Food and Drug Administration’s Orange Book are set to shorten the period during which listed patents...To view the full article, register now.
Already a subscriber? Click here to view full article